Myocardial dysfunction and cardiovascular disease in type 2 diabetes

Scandinavian Journal of Clinical and Laboratory Investigation

Volumn 76, Issue 4, 2016, Pages 271-281

  Ofstad, Anne Pernille ^a  

^a VESTRE VIKEN HOSPITAL TRUST   (Norway)

Author keywords

Cardiovascular disease; Coronary artery disease; Diabetic cardiomyopathy; Glucose lowering; Inflammation; Left ventricular dysfunction; Type 2 diabetes mellitus

Indexed keywords

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; DIASTOLIC DYSFUNCTION; EARLY INTERVENTION; ECHOCARDIOGRAPHY; FOLLOW UP; HEART FUNCTION; HUMAN; HYPERTENSION; MORBIDITY; MYOCARDIAL DISEASE; MYOCARDIAL DYSFUNCTION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; TISSUE DOPPLER IMAGING; ANALYSIS; BLOOD; CARDIOVASCULAR DISEASES; COMPLICATION; DIABETIC ANGIOPATHY; GLUCOSE BLOOD LEVEL; HEART FAILURE; RISK FACTOR;

BIOLOGICAL MARKER; GLUCOSE BLOOD LEVEL;

BIOMARKERS; BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; HEART FAILURE; HUMANS; OBESITY; RISK FACTORS;

EID: 84963588804     PISSN: 00365513     EISSN: 15027686     Source Type: Journal    
DOI: 10.3109/00365513.2016.1155230     Document Type: Review

References (115)

1. International Diabetes Federation. IDF Diabetes Atlas, 6th edn. Brussels, Belgium. Available from: http://www.idf.org/diabetesatlas 2014.
2. Diabetesforbundet. Available from: http://www.diabetes.no/Diabetes+type+2.9UFRnQ4P.ips 2010.
3. V.Chavali, S.C.Tyagi, P.K.Mishra Predictors and prevention of diabetic cardiomyopathy. Diabetes Metab Syndr Obes 2013;6:151–60.
4. D.S.Bell Diabetic cardiomyopathy. A unique entity or a complication of coronary artery disease? Diabetes Care 1995;18:708–14.
5. S.Govind, L.A.Brodin, J.Nowak, M.Quintana, S.Raumina, S.S.Ramesh, R.Keshava, S.Saha Isolated type 2 diabetes mellitus causes myocardial dysfunction that becomes worse in the presence of cardiovascular diseases: results of the myocardial doppler in diabetes (MYDID) study 1. Cardiology 2005;103:189–95.
6. S.Rubler, J.Dlugash, Y.Z.Yuceoglu, T.Kumral, A.W.Branwood, A.Grishman New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am J Cardiol 1972;30:595–602.
7. Z.Y.Fang, J.B.Prins, T.H.Marwick Diabetic cardiomyopathy: evidence, mechanisms, and therapeutic implications. Endocr Rev 2004;25:543–67.
8. M.Galderisi, K.M.Anderson, P.W.Wilson, D.Levy Echocardiographic evidence for the existence of a distinct diabetic cardiomyopathy (the Framingham Heart Study). Am J Cardiol 1991;68:85–9.
9. R.B.Devereux, M.J.Roman, M.Paranicas, M.J.O’Grady, E.T.Lee, T.K.Welty, R.R.Fabsitz, D.Robbins, E.R.Rhoades, B.V.Howard Impact of diabetes on cardiac structure and function: the strong heart study. Circulation 2000;101:2271–6.
10. M.Fischer, A.Baessler, H.W.Hense, C.Hengstenberg, M.Muscholl, S.Holmer, A.Doring, U.Broeckel, G.Riegger, H.Schunkert Prevalence of left ventricular diastolic dysfunction in the community. Results from a Doppler echocardiographic-based survey of a population sample. Eur Heart J 2003;24:320–8.
11. A.P.Ofstad, S.Urheim, H.Dalen, E.Orvik, K.I.Birkeland, L.Gullestad, W.MWF, O.E.Johansen, S.Aakhus Identification of a definite diabetic cardiomyopathy in type 2 diabetes by comprehensive echocardiographic evaluation: a cross-sectional comparison with non-diabetic weight-matched controls. J Diabetes 2015;7:779–90.
12. L.J.Boonman-de Winter, F.H.Rutten, M.J.Cramer, M.J.Landman, A.H.Liem, G.E.Rutten, A.W.Hoes High prevalence of previously unknown heart failure and left ventricular dysfunction in patients with type 2 diabetes. Diabetologia 2012;55:2154–62.
13. G.Faden, G.Faganello, S.De Feo, N.Berlinghieri, L.Tarantini, A.Di Lenarda, P.Faggiano, G.Cioffi The increasing detection of asymptomatic left ventricular dysfunction in patients with type 2 diabetes mellitus without overt cardiac disease: data from the SHORTWAVE study. Diabetes Res Clin Pract 2013;101:309–16.
14. J.K.Boyer, S.Thanigaraj, K.B.Schechtman, J.E.Perez Prevalence of ventricular diastolic dysfunction in asymptomatic, normotensive patients with diabetes mellitus. Am J Cardiol 2004;93:870–5.
15. M.K.Poulsen, J.E.Henriksen, J.Dahl, A.Johansen, O.Gerke, W.Vach, T.Haghfelt, P.F.Hoilund-Carlsen, H.Beck-Nielsen, J.E.Moller Left ventricular diastolic function in type 2 diabetes mellitus: prevalence and association with myocardial and vascular disease. Circ Cardiovasc Imaging 2010;3:24–31.
16. L.Ernande, C.Bergerot, E.R.Rietzschel, M.L.De Buyzere, H.Thibault, P.G.Pignonblanc, P.Croisille, M.Ovize, L.Groisne, P.Moulin, T.C.Gillebert, G.Derumeaux Diastolic dysfunction in patients with type 2 diabetes mellitus: is it really the first marker of diabetic cardiomyopathy? J Am Soc Echocardiogr 2011;24:1268–75 e1.
17. D.Vinereanu, E.Nicolaides, A.C.Tweddel, A.G.Fraser “Pure” diastolic dysfunction is associated with long-axis systolic dysfunction. Implications for the diagnosis and classification of heart failure. Eur J Heart Fail 2005;7:820–8.
18. A.M.From, C.G.Scott, H.H.Chen The development of heart failure in patients with diabetes mellitus and pre-clinical diastolic dysfunction a population-based study. J Am Coll Cardiol 2010;55:300–5.
19. C.W.Yancy, M.Jessup, B.Bozkurt, J.Butler, D.E.CaseyJr, M.H.Drazner, G.C.Fonarow, S.A.Geraci, T.Horwich, J.L.Januzzi, M.R.Johnson, E.K.Kasper, W.C.Levy, F.A.Masoudi, P.E.McBride, J.J.McMurray, J.E.Mitchell, P.N.Peterson, B.Riegel, F.Sam, L.W.Stevenson, W.H.Tang, E.J.Tsai, B.L.Wilkoff 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013;62:e147–239.
20. T.H.Marwick Diabetic heart disease. Heart 2006;92:296–300.
21. L.Wilhelmsen, A.Rosengren, H.Eriksson, G.Lappas Heart failure in the general population of men-morbidity, risk factors and prognosis. J Intern Med 2001;249:253–61.
22. A.Mosterd, A.W.Hoes, M.C.de Bruyne, J.W.Deckers, D.T.Linker, A.Hofman, D.E.Grobbee Prevalence of heart failure and left ventricular dysfunction in the general population; The Rotterdam Study. Eur Heart J 1999;20:447–55.
23. W.B.Kannel, M.Hjortland, W.P.Castelli Role of diabetes in congestive heart failure: the Framingham study. Am J Cardiol 1974;34:29–34.
24. I.S.Thrainsdottir, T.Aspelund, G.Thorgeirsson, V.Gudnason, T.Hardarson, K.Malmberg, G.Sigurdsson, L.Ryden The association between glucose abnormalities and heart failure in the population-based Reykjavik study. Diabetes Care 2005;28:612–16.
25. S.Sarma, R.J.Mentz, M.J.Kwasny, A.J.Fought, M.Huffman, H.Subacius, S.Nodari, M.Konstam, K.Swedberg, A.P.Maggioni, F.Zannad, R.O.Bonow, M.Gheorghiade Association between diabetes mellitus and post-discharge outcomes in patients hospitalized with heart failure: findings from the EVEREST trial. Eur J Heart Fail 2013;15:194–202.
26. J.W.Sacre, B.Franjic, C.L.Jellis, C.Jenkins, J.S.Coombes, T.H.Marwick Association of cardiac autonomic neuropathy with subclinical myocardial dysfunction in type 2 diabetes. JACC Cardiovasc Imaging 2010;3:1207–15.
27. N.Cheung, J.J.Wang, S.L.Rogers, F.Brancati, R.Klein, A.R.Sharrett, T.Y.Wong Diabetic retinopathy and risk of heart failure. J Am Coll Cardiol 2008;51:1573–8.
28. J.Hung, T.H.Teng, J.Finn, M.Knuiman, T.Briffa, S.Stewart, F.M.Sanfilippo, S.Ridout, M.Hobbs Trends from 1996 to 2007 in incidence and mortality outcomes of heart failure after acute myocardial infarction: a population-based study of 20,812 patients with first acute myocardial infarction in Western Australia. J Am Heart Assoc 2013;2:e000172
29. M.J.Leening, S.Siregar, I.Vaartjes, M.L.Bots, M.I.Versteegh, R.J.van Geuns, J.J.Koolen, J.W.Deckers Heart disease in the Netherlands: a quantitative update. Neth Heart J 2014;22:3–10.
30. D.M.Shindler, J.B.Kostis, S.Yusuf, M.A.Quinones, B.Pitt, D.Stewart, T.Pinkett, J.K.Ghali, A.C.Wilson Diabetes mellitus, a predictor of morbidity and mortality in the Studies of Left Ventricular Dysfunction (SOLVD) Trials and Registry. Am J Cardiol 1996;77:1017–20.
31. S.Boudina, E.D.Abel Diabetic cardiomyopathy revisited. Circulation 2007;115:3213–23.
32. V.L.Bodiga, S.R.Eda, S.Bodiga Advanced glycation end products: role in pathology of diabetic cardiomyopathy. Heart Fail Rev 2014;19:49–63.
33. C.Y.Shim, S.Park, E.Y.Choi, S.M.Kang, B.S.Cha, J.W.Ha, S.J.Rim, H.C.Lee, N.Chung Is albuminuria an indicator of myocardial dysfunction in diabetic patients without overt heart disease? A study with Doppler strain and strain rate imaging. Metabolism: Clinical and Experimental 2008;57:448–52.
34. P.Gaede, P.Vedel, N.Larsen, G.V.Jensen, H.H.Parving, O.Pedersen Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003;348:383–93.
35. S.R.Ommen, R.A.Nishimura, C.P.Appleton, F.A.Miller, J.K.Oh, M.M.Redfield, A.J.Tajik Clinical utility of Doppler echocardiography and tissue Doppler imaging in the estimation of left ventricular filling pressures: a comparative simultaneous Doppler-catheterization study. Circulation 2000;102:1788–94.
36. S.F.Nagueh, C.P.Appleton, T.C.Gillebert, P.N.Marino, J.K.Oh, O.A.Smiseth, A.D.Waggoner, F.A.Flachskampf, P.A.Pellikka, A.Evangelista Recommendations for the evaluation of left ventricular diastolic function by echocardiography. J Am Soc Echocardiogr 2009;22:107–33.
37. N.H.Andersen, S.H.Poulsen, H.Eiskjaer, P.L.Poulsen, C.E.Mogensen Decreased left ventricular longitudinal contraction in normotensive and normoalbuminuric patients with Type II diabetes mellitus: a Doppler tissue tracking and strain rate echocardiography study. Clin Sci (Lond) 2003;105:59–66.
38. T.H.Marwick Measurement of strain and strain rate by echocardiography: ready for prime time? J Am Coll Cardiol 2006;47:1313–27.
39. D.Vinereanu, E.Nicolaides, A.C.Tweddel, C.F.Madler, B.Holst, L.E.Boden, M.Cinteza, A.E.Rees, A.G.Fraser Subclinical left ventricular dysfunction in asymptomatic patients with Type II diabetes mellitus, related to serum lipids and glycated haemoglobin. Clin Sci (Lond) 2003;105:591–9.
40. R.Huxley, F.Barzi, M.Woodward Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies. BMJ 2006;332:73–8.
41. Centers for Disease Control. 2011 national diabetes fact sheet. Available from: http://www.cdc.gov/diabetes/pubs/pdf/ndfs_2011.pdf. 2011.
42. E.W.Gregg, Y.Li, J.Wang, N.R.Burrows, M.K.Ali, D.Rolka, D.E.Williams, L.Geiss Changes in diabetes-related complications in the United States, 1990–2010. N Engl J Med 2014;370:1514–23.
43. C.S.Fox, S.Coady, P.D.Sorlie, R.B.D’AgostinoSr, M.J.Pencina, R.S.Vasan, J.B.Meigs, D.Levy, P.J.Savage Increasing cardiovascular disease burden due to diabetes mellitus: the Framingham Heart Study. Circulation 2007;115:1544–50.
44. W.A.Muller Diabetes mellitus-long time survival. J Insur Med 1998;30:17–27.
45. K.Franklin, R.J.Goldberg, F.Spencer, W.Klein, A.Budaj, D.Brieger, M.Marre, P.G.Steg, N.Gowda, J.M.Gore Implications of diabetes in patients with acute coronary syndromes. The Global Registry of Acute Coronary Events. Arch Intern Med 2004;164:1457–63.
46. K.Malmberg, S.Yusuf, H.C.Gerstein, J.Brown, F.Zhao, D.Hunt, L.Piegas, J.Calvin, M.Keltai, A.Budaj Impact of diabetes on long-term prognosis in patients with unstable angina and non-Q-wave myocardial infarction: results of the OASIS (Organization to Assess Strategies for Ischemic Syndromes) Registry. Circulation 2000;102:1014–19.
47. K.H.Mak, D.J.Moliterno, C.B.Granger, D.P.Miller, H.D.White, R.G.Wilcox, R.M.Califf, E.J.Topol Influence of diabetes mellitus on clinical outcome in the thrombolytic era of acute myocardial infarction. GUSTO-I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. J Am Coll Cardiol 1997;30:171–9.
48. S.M.Donahoe, G.C.Stewart, C.H.McCabe, S.Mohanavelu, S.A.Murphy, C.P.Cannon, E.M.Antman Diabetes and mortality following acute coronary syndromes. Jama 2007;298:765–75.
49. W.B.Kannel Incidence and epidemiology of heart failure. Heart Fail Rev 2000;5:167–73.
50. D.K.McGuire, H.Emanuelsson, C.B.Granger, E.Magnus Ohman, D.J.Moliterno, H.D.White, D.Ardissino, J.W.Box, R.M.Califf, E.J.Topol Influence of diabetes mellitus on clinical outcomes across the spectrum of acute coronary syndromes. Findings from the GUSTO-IIb study. GUSTO IIb Investigators. Eur Heart J 2000;21:1750–8.
51. I.Iakovou, T.Schmidt, E.Bonizzoni, L.Ge, G.M.Sangiorgi, G.Stankovic, F.Airoldi, A.Chieffo, M.Montorfano, M.Carlino, I.Michev, N.Corvaja, C.Briguori, U.Gerckens, E.Grube, A.Colombo Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. Jama 2005;293:2126–30.
52. I.Moussa, M.B.Leon, D.S.Baim, W.W.O'neill, J.J.Popma, M.Buchbinder, J.Midwall, C.A.Simonton, E.Keim, P.Wang, R.E.Kuntz, J.W.Moses Impact of sirolimus-eluting stents on outcome in diabetic patients: a SIRIUS (SIRolImUS-coated Bx Velocity balloon-expandable stent in the treatment of patients with de novo coronary artery lesions) substudy. Circulation 2004;109:2273–8.
53. M.E.Farkouh, M.Domanski, L.A.Sleeper, F.S.Siami, G.Dangas, M.Mack, M.Yang, D.J.Cohen, Y.Rosenberg, S.D.Solomon, A.S.Desai, B.J.Gersh, E.A.Magnuson, A.Lansky, R.Boineau, J.Weinberger, K.Ramanathan, J.E.Sousa, J.Rankin, B.Bhargava, J.Buse, W.Hueb, C.R.Smith, V.Muratov, S.Bansilal, S.King3rd, M.Bertrand, V.Fuster Strategies for multivessel revascularization in patients with diabetes. N Engl J Med 2012;367:2375–84.
54. S.M.Haffner, S.Lehto, T.Ronnemaa, K.Pyorala, M.Laakso Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998;339:229–34.
55. U.Bulugahapitiya, S.Siyambalapitiya, J.Sithole, I.Idris Is diabetes a coronary risk equivalent? Systematic review and meta-analysis. Diabet Med 2009;26:142–8.
56. J.Kuusisto, M.Laakso Update on type 2 diabetes as a cardiovascular disease risk equivalent. Curr Cardiol Rep 2013;15:331.
57. M.Laakso, J.Kuusisto Insulin resistance and hyperglycaemia in cardiovascular disease development. Nature Reviews Endocrinology 2014;10:293–302.
58. M.C.Calle, M.L.Fernandez Inflammation and type 2 diabetes. Diabetes Metab 2012;38:183–91.
59. P.Libby Inflammation and cardiovascular disease mechanisms. Am J Clin Nutr 2006;83:456S–60s.
60. A.P.Burke, F.D.Kolodgie, A.Zieske, D.R.Fowler, D.K.Weber, P.J.Varghese, A.Farb, R.Virmani Morphologic findings of coronary atherosclerotic plaques in diabetics: a postmortem study. Arterioscler Thromb Vasc Biol 2004;24:1266–71.
61. A.D.Pradhan, P.M.Ridker Do atherosclerosis and type 2 diabetes share a common inflammatory basis? Eur Heart J 2002;23:831–4.
62. A.D.Pradhan, J.E.Manson, N.Rifai, J.E.Buring, P.M.Ridker C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. Jama 2001;286:327–34.
63. S.Mirza, M.Hossain, C.Mathews, P.Martinez, P.Pino, J.L.Gay, A.Rentfro, J.B.McCormick, S.P.Fisher-Hoch Type 2-diabetes is associated with elevated levels of TNF-alpha, IL-6 and adiponectin and low levels of leptin in a population of Mexican Americans: a cross-sectional study. Cytokine 2012;57:136–42.
64. P.M.Ridker, C.H.Hennekens, J.E.Buring, N.Rifai C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000;342:836–43.
65. P.M.Ridker, N.Rifai, M.J.Stampfer, C.H.Hennekens Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 2000;101:1767–72.
66. J.Danesh, S.Kaptoge, A.G.Mann, N.Sarwar, A.Wood, S.B.Angleman, F.Wensley, J.P.Higgins, L.Lennon, G.Eiriksdottir, A.Rumley, P.H.Whincup, G.D.Lowe, V.Gudnason Long-term interleukin-6 levels and subsequent risk of coronary heart disease: two new prospective studies and a systematic review. PLoS Med 2008;5:e78
67. C.Herder, B.Schottker, D.Rothenbacher, M.Roden, H.Kolb, H.Muller, H.Brenner Interleukin-6 in the prediction of primary cardiovascular events in diabetes patients: results from the ESTHER study. Atherosclerosis 2011;216:244–7.
68. A.P.Ofstad, L.Gullestad, E.Orvik, S.Aakhus, K.Endresen, T.Ueland, P.Aukrust, M.W.Fagerland, K.I.Birkeland, O.E.Johansen Interleukin-6 and activin A are independently associated with cardiovascular events and mortality in type 2 diabetes: the prospective Asker and Baerum Cardiovascular Diabetes (ABCD) cohort study. Cardiovasc Diabetol 2013;12:126
69. M.P.Hedger, D.M.de Kretser The activins and their binding protein, follistatin-Diagnostic and therapeutic targets in inflammatory disease and fibrosis. Cytokine Growth Factor Rev 2013;24:285–95.
70. O.Hashimoto, M.Funaba Activin in glucose metabolism. Vitam Horm 2011;85:217–34.
71. H.Wu, M.Wu, Y.Chen, C.A.Allan, D.J.Phillips, M.P.Hedger Correlation between blood activin levels and clinical parameters of Type 2 Diabetes. Exp Diabetes Res 2012;2012:410579
72. A.Yndestad, T.Ueland, E.Oie, G.Florholmen, B.Halvorsen, H.Attramadal, S.Simonsen, S.S.Froland, L.Gullestad, G.Christensen, J.K.Damas, P.Aukrust Elevated levels of activin A in heart failure: potential role in myocardial remodeling. Circulation 2004;109:1379–85.
73. T.Ueland, P.Aukrust, S.Aakhus, C.Smith, K.Endresen, K.I.Birkeland, L.Gullestad, O.E.Johansen Activin A and cardiovascular disease in type 2 diabetes mellitus. Diab Vasc Dis Res 2012;9:234–7.
74. G.O.Andersen, T.Ueland, E.C.Knudsen, H.Scholz, A.Yndestad, A.Sahraoui, C.Smith, T.Lekva, K.Otterdal, B.Halvorsen, I.Seljeflot, P.Aukrust Activin A levels are associated with abnormal glucose regulation in patients with myocardial infarction: potential counteracting effects of activin A on inflammation. Diabetes 2011;60:1544–51.
75. A.P.Ofstad, G.R.Ulimoen, E.Orvik, K.Endresen, K.I.Birkeland, T.Ueland, P.Aukrust, L.Gullestad, O.E.Johansen Activin A is associated with higher extent of coronary artery disease (CAD), but not with increased rate of progression during 7 years follow-up, in subjects with type 2 diabetes Abstract presented at the 74th Scientific Session American Diabetes Association, 2014, San Francisco, USA 2014.
76. A.Gokcel, M.Aydin, F.Yalcin, A.F.Yapar, M.E.Ertorer, A.K.Ozsahin, H.Muderrisoglu, A.Aktas, N.Guvener, M.Akbaba Silent coronary artery disease in patients with type 2 diabetes mellitus. Acta Diabetol 2003;40:176–80.
77. B.Janand-Delenne, B.Savin, G.Habib, M.Bory, P.Vague, V.Lassmann-Vague Silent myocardial ischemia in patients with diabetes: who to screen. Diabetes Care 1999;22:1396–400.
78. E.Grossman, F.H.Messerli Diabetic and hypertensive heart disease. Ann Intern Med 1996;125:304–10.
79. A.I.Vinik, R.E.Maser, B.D.Mitchell, R.Freeman Diabetic autonomic neuropathy. Diabetes Care 2003;26:1553–79.
80. R.E.Vlietstra, R.A.Kronmal, R.L.Frye, A.K.Seth, F.E.Tristani, T.Killip3rd. Factors affecting the extent and severity of coronary artery disease in patients enrolled in the coronary artery surgery study. Arteriosclerosis 1982;2:208–15.
81. M.Soinio, J.Marniemi, M.Laakso, S.Lehto, T.Ronnemaa High-sensitivity C-reactive protein and coronary heart disease mortality in patients with type 2 diabetes: a 7-year follow-up study. Diabetes Care 2006;29:329–33.
82. S.Kaptoge, E.Di Angelantonio, L.Pennells, A.M.Wood, I.R.White, P.Gao, M.Walker, A.Thompson, N.Sarwar, M.Caslake, A.S.Butterworth, P.Amouyel, G.Assmann, S.J.Bakker, E.L.Barr, E.Barrett-Connor, E.J.Benjamin, C.Bjorkelund, H.Brenner, E.Brunner, R.Clarke, J.A.Cooper, P.Cremer, M.Cushman, G.R.Dagenais, R.B.D’AgostinoSr, R.Dankner, G.Davey-Smith, D.Deeg, J.M.Dekker, G.Engstrom, A.R.Folsom, F.G.Fowkes, J.Gallacher, J.M.Gaziano, S.Giampaoli, R.F.Gillum, A.Hofman, B.V.Howard, E.Ingelsson, H.Iso, T.Jorgensen, S.Kiechl, A.Kitamura, Y.Kiyohara, W.Koenig, D.Kromhout, L.H.Kuller, D.A.Lawlor, T.W.Meade, A.Nissinen, B.G.Nordestgaard, A.Onat, D.B.Panagiotakos, B.M.Psaty, B.Rodriguez, A.Rosengren, V.Salomaa, J.Kauhanen, J.T.Salonen, J.A.Shaffer, S.Shea, I.Ford, C.D.Stehouwer, T.E.Strandberg, R.W.Tipping, A.Tosetto, S.Wassertheil-Smoller, P.Wennberg, R.G.Westendorp, P.H.Whincup, L.Wilhelmsen, M.Woodward, G.D.Lowe, N.J.Wareham, K.T.Khaw, N.Sattar, C.J.Packard, V.Gudnason, P.M.Ridker, M.B.Pepys, S.G.Thompson, J.Danesh C-reactive protein, fibrinogen, and cardiovascular disease prediction. N Engl J Med 2012;367:1310–20.
83. B.Schottker, C.Herder, D.Rothenbacher, M.Roden, H.Kolb, H.Muller, H.Brenner Proinflammatory cytokines, adiponectin, and increased risk of primary cardiovascular events in diabetic patients with or without renal dysfunction: results from the ESTHER study. Diabetes Care 2013;36:1703–11.
84. G.Lowe, M.Woodward, G.Hillis, A.Rumley, Q.Li, S.Harrap, M.Marre, P.Hamet, A.Patel, N.Poulter, J.Chalmers Circulating inflammatory markers and the risk of vascular complications and mortality in people with type 2 diabetes and cardiovascular disease or risk factors: the ADVANCE study. Diabetes 2014;63:1115–23.
85. A.Y.Wang, M.Wang, C.W.Lam, I.H.Chan, Y.Zhang, J.E.Sanderson Left ventricular filling pressure by Doppler echocardiography in patients with end-stage renal disease. Hypertension 2008;52:107–14.
86. G.S.Hillis, J.E.Moller, P.A.Pellikka, B.J.Gersh, R.S.Wright, S.R.Ommen, G.S.Reeder, J.K.Oh Noninvasive estimation of left ventricular filling pressure by E/e′ is a powerful predictor of survival after acute myocardial infarction. J Am Coll Cardiol 2004;43:360–7.
87. H.Kitaoka, T.Kubo, K.Hayashi, N.Yamasaki, Y.Matsumura, T.Furuno, Y.L.Doi Tissue Doppler imaging and prognosis in asymptomatic or mildly symptomatic patients with hypertrophic cardiomyopathy. Eur Heart J Cardiovasc Imaging 2013;14:544–9.
88. P.Blomstrand, M.Engvall, K.Festin, T.Lindstrom, T.Lanne, E.Maret, F.H.Nystrom, J.Maret-Ouda, C.J.Ostgren, J.Engvall Left ventricular diastolic function, assessed by echocardiography and tissue Doppler imaging, is a strong predictor of cardiovascular events, superior to global left ventricular longitudinal strain, in patients with type 2 diabetes. Eur Heart J Cardiovasc Imaging 2015;16:1000–7.
89. I.M.Stratton, A.I.Adler, H.A.Neil, D.R.Matthews, S.E.Manley, C.A.Cull, D.Hadden, R.C.Turner, R.R.Holman Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. Bmj 2000;321:405–12.
90. C.Iribarren, A.J.Karter, A.S.Go, A.Ferrara, J.Y.Liu, S.Sidney, J.V.Selby Glycemic control and heart failure among adult patients with diabetes. Circulation 2001;103:2668–73.
91. J.Juhaeri, S.Gao, W.S.Dai Incidence rates of heart failure, stroke, and acute myocardial infarction among Type 2 diabetic patients using insulin glargine and other insulin. Pharmacoepidemiol Drug Saf 2009;18:497–503.
92. B.M.Scirica, D.L.Bhatt, E.Braunwald, P.G.Steg, J.Davidson, B.Hirshberg, P.Ohman, R.Frederich, S.D.Wiviott, E.B.Hoffman, M.A.Cavender, J.A.Udell, N.R.Desai, O.Mozenson, D.K.McGuire, K.K.Ray, L.A.Leiter, I.Raz Saxagliptin and cardiovascular outcomes in patients with Type 2 diabetes mellitus. N Engl J Med 2013;369:1317–26.
93. R.W.Nesto, D.Bell, R.O.Bonow, V.Fonseca, S.M.Grundy, E.S.Horton, M.Le Winter, D.Porte, C.F.Semenkovich, S.Smith, L.H.Young, R.Kahn Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003. Circulation 2003;108:2941–8.
94. L.R.Peterson, C.R.McKenzie, J.E.Schaffer Diabetic cardiovascular disease: getting to the heart of the matter. J Cardiovasc Transl Res 2012;5:436–45.
95. H.C.Gerstein, M.E.Miller, R.P.Byington, D.C.GoffJr, J.T.Bigger, J.B.Buse, W.C.Cushman, S.Genuth, F.Ismail-Beigi, R.H.GrimmJr, J.L.Probstfield, D.G.Simons-Morton, W.T.Friedewald Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545–59.
96. D.Castagno, J.Baird-Gunning, P.S.Jhund, G.Biondi-Zoccai, M.R.MacDonald, M.C.Petrie, F.Gaita, J.J.McMurray Intensive glycemic control has no impact on the risk of heart failure in type 2 diabetic patients: evidence from a 37,229 patient meta-analysis. Am Heart J 2011;162:938–48 e2.
97. J.B.Green, M.A.Bethel, P.W.Armstrong, J.B.Buse, S.S.Engel, J.Garg, R.Josse, K.D.Kaufman, J.Koglin, S.Korn, J.M.Lachin, D.K.McGuire, M.J.Pencina, E.Standl, P.P.Stein, S.Suryawanshi, F.Van de Werf, E.D.Peterson, R.R.Holman Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 2015;373:232–42.
98. B.Zinman, C.Wanner, J.M.Lachin, D.Fitchett, E.Bluhmki, S.Hantel, M.Mattheus, T.Devins, O.E.Johansen, H.J.Woerle, U.C.Broedl, S.E.Inzucchi Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med 2015;373:2117–28.
99. H.von Bibra, A.Hansen, V.Dounis, T.Bystedt, K.Malmberg, L.Ryden Augmented metabolic control improves myocardial diastolic function and perfusion in patients with non-insulin dependent diabetes. Heart 2004;90:1483–4.
100. H.von Bibra, T.Siegmund, A.Hansen, J.Jensen, P.M.Schumm-Draeger [Augmentation of myocardial function by improved glycemic control in patients with type 2 diabetes mellitus]. Dtsch Med Wochenschr 2007;132:729–34.
101. H.von Bibra, M.St John Sutton Diastolic dysfunction in diabetes and the metabolic syndrome: promising potential for diagnosis and prognosis. Diabetologia 2010;53:1033–45.
102. C.Jarnert, L.Landstedt-Hallin, K.Malmberg, A.Melcher, J.Ohrvik, H.Persson, L.Ryden A randomized trial of the impact of strict glycaemic control on myocardial diastolic function and perfusion reserve: a report from the DADD (Diabetes mellitus And Diastolic Dysfunction) study. Eur J Heart Fail 2009;11:39–47.
103. V.D.Vintila, A.Roberts, D.Vinereanu, A.G.Fraser Progression of subclinical myocardial dysfunction in type 2 diabetes after 5 years despite improved glycemic control. Echocardiography 2012;29:1045–53.
104. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS). Group. Lancet 1998;352:837–53.
105. A.Patel, S.MacMahon, J.Chalmers, B.Neal, L.Billot, M.Woodward, M.Marre, M.Cooper, P.Glasziou, D.Grobbee, P.Hamet, S.Harrap, S.Heller, L.Liu, G.Mancia, C.E.Mogensen, C.Pan, N.Poulter, A.Rodgers, B.Williams, S.Bompoint, B.E.de Galan, R.Joshi, F.Travert Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560–72.
106. R.R.Holman, S.K.Paul, M.A.Bethel, D.R.Matthews, H.A.Neil 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577–89.
107. F.M.Turnbull, C.Abraira, R.J.Anderson, R.P.Byington, J.P.Chalmers, W.C.Duckworth, G.W.Evans, H.C.Gerstein, R.R.Holman, T.E.Moritz, B.C.Neal, T.Ninomiya, A.A.Patel, S.K.Paul, F.Travert, M.Woodward Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia 2009;52:2288–98.
108. N.Sattar Revisiting the links between glycaemia, diabetes and cardiovascular disease. Diabetologia 2013;56:686–95.
109. S.Ross, H.C.Gerstein, J.Eikelboom, S.S.Anand, S.Yusuf, G.Pare Mendelian randomization analysis supports the causal role of dysglycaemia and diabetes in the risk of coronary artery disease. Eur Heart J 2015;36:1454–62.
110. A.P.Ofstad, O.E.Johansen, L.Gullestad, K.I.Birkeland, E.Orvik, M.W.Fagerland, S.Urheim, S.Aakhus Neutral impact on systolic and diastolic cardiac function of 2 years of intensified multi-intervention in type 2 diabetes: the randomized controlled Asker and Baerum Cardiovascular Diabetes (ABCD) study. Am Heart J 2014;168:280–8.e2.
111. O.E.Johansen, L.Gullestad, K.G.Blaasaas, E.Orvik, K.I.Birkeland Effects of structured hospital-based care compared with standard care for Type 2 diabetes – The Asker and Baerum Cardiovascular Diabetes Study, a randomized trial. Diabet Med 2007;24:1019–27.
112. A.P.Ofstad, G.R.Ulimoen, K.I.Birkeland, E.Orvik, L.Gullestad, O.E.Johansen Long-term glycaemic benefit of intensified multiintervention for type 2 diabetes – a 5-year follow-up study of the asker and Baerum Cardiovascular Diabetes (ABCD) study. Abstract presented at the 4th Annual Meeting D&CVD EASD study group, Munich, Germany 2011.
113. P.Gaede, H.Lund-Andersen, H.H.Parving, O.Pedersen Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008;358:580–91.
114. S.J.Griffin, K.Borch-Johnsen, M.J.Davies, K.Khunti, G.E.Rutten, A.Sandbaek, S.J.Sharp, R.K.Simmons, M.van den Donk, N.J.Wareham, T.Lauritzen Effect of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with type 2 diabetes detected by screening (ADDITION-Europe): a cluster-randomised trial. Lancet 2011;378:156–67.
115. V.Dzau, E.Braunwald Resolved and unresolved issues in the prevention and treatment of coronary artery disease: a workshop consensus statement. Am Heart J 1991;121:1244–63.